# A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

> **NCT06785116** · PHASE4 · RECRUITING · sponsor: **University of Michigan** · enrollment: 200 (estimated)

## Conditions studied

- Gestational Hypertension
- Hypertension in Pregnancy
- Pre-Eclampsia
- Superimposed Pre-Eclampsia
- Cardiovascular Complication

## Interventions

- **DRUG:** Placebo
- **DRUG:** Dapagliflozin 10mg Tab

## Key facts

- **NCT ID:** NCT06785116
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-02
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06785116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06785116, "A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06785116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*